

*Supporting Information for*

## **Copper (II)/cis-platinum -loaded nanogels as an adjuvant potentiate disulfiram antitumor efficacy**

**Yu Geng<sup>‡a,b</sup>, Rui Sun<sup>‡\*a,b</sup>, Yifan Zhang<sup>a</sup>, Zhuxian Zhou<sup>a,b</sup>, Youqing Shen<sup>\*a,b</sup>**

<sup>a</sup> Center for Bionanoengineering and Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China

<sup>b</sup> ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, Zhejiang 311215, China

\*Corresponding author.

E-mail: [sx19900108@126.com](mailto:sx19900108@126.com) (Rui Sun), [shenyq@zju.edu.cn](mailto:shenyq@zju.edu.cn) (Youqing Shen)

‡ Yu Geng and Rui Sun contributed equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

**Fig. S1** SEC curve of PGMA.

**Fig. S2**  $^1\text{H-NMR}$  spectrums of PGMA (solvent:  $\text{CDCl}_3$ ), PGMA-SAR, and PGMA-IDA (solvent:  $\text{D}_2\text{O}$ ).

**Fig. S3** Confocal microscopy imaging of the intracellular  $^{\text{RhB}}$ PGMA and  $^{\text{RhB}}\text{NG}_{\text{Cu}^{2+}}$  nanogels in 4T1 cells.

**Fig. S4** Size distribution patterns of PGMA-SAR/CDDP at different molar ratios.


**Fig. S5** The ITC titration and fitting curves of adding PGMA-SAR solution to CDDP.

**Fig. S6** Size distribution patterns of  $\text{NG}_{\text{CDDP}}$  in water and cell culture medium containing 10% serum.


**Fig. S7** The blood Pt concentration as a function of time in the ICR mice after *i.v.* injection of CDDP or  $\text{NG}_{\text{CDDP}}$  at a CDDP dose of 2 mg/kg.

**Fig. S8** Histological analysis of major organs in 4T1 cancer model after *i.v.* injection of  $\text{CuCl}_2$  or  $\text{NG}_{\text{Cu}^{2+}}$  at a copper ions dose of 0.5 mg/kg.


**Fig. S9** Histological analysis of kidney in 4T1 cancer model after *i.v.* injection of CDDP or  $\text{NG}_{\text{CDDP}}$  at a CDDP dose of 2 mg/kg.




**Fig. S1** SEC curve of PGMA.




**Fig. S2**  $^1\text{H-NMR}$  spectrums of PGMA (solvent:  $\text{CDCl}_3$ ), PGMA-SAR, and PGMA-IDA (solvent:  $\text{D}_2\text{O}$ ).




**Fig. S3** Confocal microscopy imaging of the intracellular  $\text{RhBPGMA}$  and  $\text{RhBNG}_{\text{Cu}^{2+}}$  nanogels in 4T1 cells. Confocal microscopy images taken from the RhB fluorescence channel (red) and merged with the images taken from the Hoechst fluorescence channel (blue) and Lyso-Tracker Green (green) of the cells after 2 h incubation with  $\text{RhBPGMA}$  and  $\text{RhBNG}_{\text{Cu}^{2+}}$  nanogels (the RhB - eq. dose used for the experiments was  $0.5 \mu\text{g}/\text{mL}$ ). The cells were imaged using a  $60\times$  oil-immersion objective; scale bars:  $20 \mu\text{m}$ .




**Fig. S4** Size distribution patterns of PGMA-SAR/CDDP at different molar ratios.




**Fig. S5** The ITC titration and fitting curves of adding PGMA-SAR solution ( 50 mM) to CDDP (10 mM) at 25 °C




**Fig. S6** Size distribution patterns of NG<sub>CDDP</sub> in water and cell culture medium containing 10% serum.



**Fig. S7** The blood Pt concentration as a function of time in the ICR mice after *i.v.* injection of CDDP or NG<sub>CDDP</sub> at a CDDP dose of 2 mg/kg.



**Fig. S8** Histological analysis of major organs in 4T1 cancer model after *i.v.* injection of  $\text{CuCl}_2$  or  $\text{NG}_{\text{Cu}^{2+}}$  at a copper ions dose of 0.5 mg/kg (scale bar: 1 mm).



**Fig. S9** Histological analysis of kidney in 4T1 cancer model after *i.v.* injection of CDDP or  $\text{NG}_{\text{CDDP}}$  at a CDDP dose of 2 mg/kg (scale bar: 1 mm).